Gilead Sciences (GILD) Income from Continuing Operations (2009 - 2026)
Gilead Sciences' Income from Continuing Operations was -$10.5 billion in Q2 2026, compared with $1.96 billion a year earlier.
Powered by 
Analysis
Gilead Sciences (GILD) Income from Continuing Operations (2009 - 2026) Analysis & Trends
On a trailing twelve-month basis, Gilead Sciences' Income from Continuing Operations was -$3.24 billion through Jun 30, 2026; for FY2025, it came in at $8.51 billion.
- Income from Continuing Operations shows a five-year compound annual growth rate of 148.9% (FY2020 to FY2025).
- In earlier years, Income from Continuing Operations was $479 million in FY2024 (-91.5%), $5.61 billion in FY2023 (+22.9%), $4.57 billion in FY2022 (-26.4%) and $6.2 billion in FY2021.
- The Q2 2026 figure marks the lowest quarterly Income from Continuing Operations in data going back to Q1 2009.
- Compared with a year earlier, Income from Continuing Operations was higher in five of the last six quarters, with growth averaging 37.5%.
- The best year-over-year quarter for Income from Continuing Operations over five years was Q3 2021 (growth of 632.6%); the worst was Q1 2022 (a decline of 99.3%).
- Per Business Quant data, GILD's Income from Continuing Operations in the three quarters before Q2 2026 was $2.02 billion (Q1 2026), $2.18 billion (Q4 2025) and $3.05 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 3.62 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 5.28 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 3.09 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | -246.00 Mn |
| 10 | Vertex Pharmaceuticals | 128.38 Bn | 100.39 Bn | 2.84 Bn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.50 Bn |
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.18 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 984.00 Mn |
| Dec 31, 2022 | 1.63 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 376.00 Mn |
| Sep 30, 2021 | 2.59 Bn |
API Access
Gilead Sciences Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=GILD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "GILD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=GILD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();